The authors evaluated children aged younger than 18 years who were HIV-exposed but uninfected with at least one head circumference measurement while enrolled in the Surveillance Monitoring for ART Toxicities (SMARTT) study at 22 clinical sites in the USA, including Puerto Rico. These findings support consideration of alternatives to efavirenz as part of first-line antiretroviral therapy for pregnant women.

9th December 2019 • comment